CTGTAC CV: David Bartlett, M.D. - Food and Drug … Address: University of Pittsburgh E-Mail: [email protected] Dept. of Surgery 5150 Centre Avenue Business Phone: 412-692-2852 UPMC

Curriculum Vitae David L. Bartlett, MD Revised 11/10/14 Page 1

Curriculum Vitae David L. Bartlett, M.D. University of Pittsburgh

School of Medicine

BIOGRAPHICAL Name: David L. Bartlett Birth date: --b(6)------- Home Address: ---b(6)------------------ Birth place: --b(6)-------- ------------------------- Home Phone: --b(6)--------------- Citizenship: -b(6)-- Business Address: University of Pittsburgh E-Mail: [email protected] Dept. of Surgery 5150 Centre Avenue Business Phone: 412-692-2852 UPMC Cancer Pavilion, Rm.415 Pittsburgh, PA 15232 Business Fax: 412-692-2520

EDUCATION and TRAINING Undergraduate: 1979-1983 Rice University B.A., 1983 Roy Houston, Texas Cum Laude Scholar Graduate: 1983-1987 University of Texas M.D., 1987 Medicine

Medical School at Houston Alpha Omega Alpha Houston, Texas Sandoz Award for

Academic Achievement Post-Graduate: 1987 - 1993 Hospital of the University --b(6)------------- Surgery of Pennsylvania Resident Philadelphia, Pennsylvania 1993 - 1995 Memorial Sloan-Kettering --b(6)------------- Fellow, Surgical Surgical Cancer Center Oncology New York, NY


Research Fellowships: 1984-1987 M.D. Anderson Hospital --b(6)------------- Department of

Houston, TX Research Fellow Developmental Therapeutics 1989-1991 Department of Surgery M. Torosian, MD Harrison Hospital of the University NIH Research Dept. of Pennsylvania Fellowship Surgical IT32CA09619 Research Clinical Fellowship: 1993 - 1995 Memorial Sloan-Kettering --b(6)------------------- Cancer Center Surgical Oncology New York, NY Fellow 1994 – 1995 American Cancer Society --b(6)---------------------- Award # 94-138-1 Clinical Fellow Surgical Oncology

APPOINTMENTS and POSITIONS

7/1/95 - 6/30/96 National Cancer Institute Special Expert Surgery Branch 7/1/96 – 10/01 National Cancer Institute Senior Surgery Branch Investigator

7/1/96- 10/01 Uniformed Services Assistant University of Health Sciences Professor 10/01 – 2005 University of Pittsburgh Visiting Associate Department of Surgery Professor and Chief, Division of Surgical Oncology 2005 – Present University of Pittsburgh Professor of Surgery Department of Surgery Vice Chair,

Department of Surgery


2006 – Present University of Pittsburgh Bernard Fisher

Department of Surgery Endowed Professor of Surgery

2011 – Present University of Pittsburgh Professor in Clinical Clinical and Translational and Translational Science Science Institute University and Medical School Positions: 2001 - 2010 - Chief, Division of Surgical Oncology 2001 - present - UPCI Executive Council Committee Member 2001 - present - Director, Surgical Oncology Fellowship Program 2001 - present - Chair, Surgical Oncology Selection Committee 2004 - present - Director, David C. Koch Regional Perfusion Cancer Therapy Center 2004 – present - Director, Surgical Services for UPCI 2005 – present - Director, Specialty Care Clinics for UPMC Cancer Centers 2007 – 2009 - University of Pittsburgh Physicians Executive Committee Member 2007 – 2009 - UPCI Director Search Committee Member 2008 – 2012 - Standing Committee for Non-Tenured Faculty Promotions and Appointments 2008 – present - Surgical Team Innovation Committee Physician/Anesthesia 2009 – present - Director of Multidisciplinary Disease Site Clinical and Research Programs 2009 - 2010 - University of Pittsburgh Physicians Board of Directors 2010 - present- Chairman, Passavant Robotic Oversight Committee National/International Positions: 2001 – Present - Ad hoc reviewer: Clinical Cancer Research, Cancer Research, Gene

Therapy, Human Gene Therapy; Annals of Surgical Oncology, Cancer, Journal of Immunology, Cancer Chemotherapy and Pharmacology, Scientific World Journal, American Journal of Pathology, Melanoma Research, Plos One, World Journal of Surgical Oncology, Translational Research 2003 – 2008 - Scientific Program Committee, Society of Surgical Oncology 2003 – Present - Scientific Review Committee: Pittsburgh Foundation 2005 – Present - Director, Regional Cancer Therapies, Annual meeting. 2005 – 2006 - Chair, Scientific Program Committee, Society of Surgical Oncology 2005 – 2007 - NIH Study Section: Ad Hoc Reviewer of T32 training grants; K99, K12

training grants; Program Project Grants 2006 – 2009 - Executive Council member, Society of Surgical Oncology 2007 – 2011 - NIH Study Section Member: NIH/NCI-F – T32/K99/R00 grants 2008 – 2013 Chair, Program Directors Committee, Society of Surgical Oncology


2010 – Present - Host, National SSO Videoconference 2010 – Present - Host, National Perfusion Videoconference 2011 – Present Board of Directors, Jeffrey Ewing Foundation 2011 – Present - Co-Director, SSO Fellows Institute 2012 – Present - Member, Educational Products Committee, Society of Surgical Oncology 2014 - Treasurer, Society of Surgical Oncology

CERTIFICATION and LICENSURE

Specialty Certification: American Board of Surgeons November 1994 Medical Licensure: Maryland D47564 Pennsylvania MD-044852-E

MEMBERSHIPS in PROFESSIONAL and SCIENTIFIC SOCIETIES American Medical Association 1987 - present Pennsylvania Medical Society 1989 - 1993 Society of Surgical Oncology 1993 - present Society of Laparoendoscopic Surgeons 1993 - 2000 American Society of Gene Therapy 2000 - present Society of University Surgeons 2000 - present American Society of Clinical Oncology 2001 - present American Association for Cancer Research 2004 - present American College of Surgeons 2006-present American Surgical Association 2006-present American Association for Endocrine Surgeons 2007-present Pittsburgh Surgical Society 2008-2010 American Society of Peritoneal Surface Malignancies 2009 - Present

HONORS

William Inouye award for excellence in teaching by a surgical resident 1991 Scientific Program Director, Society of Surgical Oncology Annual Meeting 2005 Elected as Councillor-at-Large on the SSO Executive Council – 3 year term 2006 Appointed Bernard Fisher Endowed Professor of Surgery 2006 William A. Maddox Lecturer, University of Alabama 2007 Memorial Sloan Kettering Distinguished Visiting Professor 2009 UPCI Leo H. Creip Award for Excellence in Patient Care 2011 ACES award for Excellence in Patient Care 2012


PUBLICATIONS Refereed Articles: 1. Bartlett DL, Charland SL, Torosian MH: Glucose metabolism and hormone treatment in

cancer cachexia. Surgical Forum 42:14-16, 1991.

2. Redmond HP, Schuchter L, Bartlett DL, Kelly CJ, Shou J, Leon P, and Daly JM. Anti-neoplastic effects of interleukin-4. J Surg Res. 52(4):406-411, 1992.

3. Torosian MH, Bartlett DL, Chatzidakis C, Stein TP: Effect of tumor burden on futile glucose and lipid cycling in tumor-bearing animals. J Surg Res. 55(1):68-73, 1993.

4. Torosian MH, Bartlett DL: Inhibition of tumor metastasis by a circulating suppressor factor. J Surg Res. 55(1): 74-79, 1993.

5. Charland SL, Bartlett DL, Davis R, Torosian MH: Effect of protein-calorie malnutrition on methotrexate pharmacokinetics. JPEN 18(1):45-49, 1994.

6. Bartlett DL, Charland S, Torosian MH: Growth hormone, insulin, and somatostatin therapy of cancer cachexia. Cancer. 73(5):1499-504, 1994.

7. Bartlett DL, Charland S, Torosian MH: Effect of glutamine on tumor and host growth. Annals of Surgical Oncology. 2(1):71-76, 1995.

8. Bartlett DL, Charland S, Stein TP, Torosian MH: Effect of growth hormone and protein intake on tumor growth and host cachexia. Surgery. 117(3):260-267, 1995

9. Bartlett DL, Torosian MH: Biochemical and biological effects of somatostatin therapy on tumor growth and host metabolism. International Journal of Oncology. 1995.

10. Bartlett DL, Conlon K, Gerdes H, Karpeh M: Laparoscopic ultrasound: the best pretreatment staging modality in gastric adenocarcinoma? Surgery. 118(3):562-566, 1995.

11. Bartlett DL, Cohen A, Huttner R, Torosian MH: Adrenal pseudocyst in pregnancy Surgery. 118(3):567-570, 1995.

12. Bartlett DL, Charland S, Torosian MH: Reversal of Tumor-Associated Hyperglucagonemia as Treatment for Cancer Cachexia. Surgery. 118(1): 87-97, 1995.

13. Charland S, Bartlett DL, Torosian MH: A significant methotrexate-glutamine pharmacokinetic interaction. Nutrition. 11(2): 175-177, 1995.

14. Bartlett DL, Karpeh MJ, Philippa D, Brennan MF: Long term follow-up after curative surgery for early gastric lymphoma Ann Surg. 223(1):53-62, 1996.

15. Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH: Long-term results after resection for gallbladder cancer -- implications for staging and management. Ann Surg. 224(5): 639-646, 1996.

16. Bartlett DL, Schwartz LH, Klimstra D, Blumgart LH: Diagnosis and treatment of focal nodular hyperplasia. J Hep Bil Pancr Surg. 3:111-121, 1996.


17. Bartlett DL, Fong Y, Blumgart LH: Complete resection of the caudate lobe of the liver: technique and results. Br J Surg 83: 1076-1081, 1996.

18. Ma G, Turner E, Jaskowiak N, Sarraf P, Bartlett DL, Fraker D, Alexander HR: Obese gene expression is acutely regulated by tumor necrosis factor during sublethal endotoxemia in mice. Surg Forum. 47:17-20, 1996.

19. Alexander HR, Fraker DL, Bartlett DL: Isolated Limb Perfusion for Malignant Melanoma. Seminars in Surgical Oncology. 12: 416-428, 1996.

20. Ma GY, Bartlett DL, Reed E, Figg WD, Lush RM, Lee KB, Libutti, SK, Alexander HR: Continuous Hyperthermic Peritoneal Perfusion with Cisplatin for the Treatment of Peritoneal Mesothelioma. Cancer J Sci Am. 3: 174-179, 1997.

21. Vargas HI, Kavhoussi LR, Bartlett DL, Wagner JR, Venzon DJ, Fraker DL, Alexander HR, Linehan MW, Walther MM: Laparoscopic Adrenalectomy: A New Standard of Care J Urology. 79: 673-678, 1997.

22. Bartlett DL, Ma GY, Alexander HR, Libutti SK, Fraker DL,: Isolated Limb Reperfusion with Tumor Necrosis Factor and Melphalan for Extremity Melanoma after Failure of Isolated Limb Perfusion with Chemotherapeutics Cancer. 80: 2084-2990, 1997.

23. Brown CK, Bartlett DL, Doppman JL, Gorden P, Libutti SK, Fraker DL, Shawker TH, Skarulis MC, Alexander HR: Intra-arterial Calcium Stimulation and Intraoperative Ultrasonography in the Localization and Resection of Insulinomas. Surgery. 122: 189-1194, 1997.

24. Wu PC, Alexander HR, Bartlett DL, Doppman JL, Fraker DL, Norton JA, Gibril F, Fogt F, Jensen RT: A Prospective Analysis of the Frequency, Location, and Curability of Ectopic (non-pancreaticoduodenal, non-nodal) Gastrinoma Surgery. 122: 1176-1182, 1997.

25. Libutti SK, Bartlett DL, Doppman JL, Fraker DL, Marx S, Spiegel A, Skarulis M, Alexander HR: The Role for Thyroid Resection During Reoperation for Persistent or Recurrent Hyperparathyroidism.Surgery. 122: 1183-1188, 1997.

26. Riker A, Libutti SK, Bartlett DL: Advances in the early detection, diagnosis and staging

of pancreatic cancer. Surg. Oncol. Nov; 6 (3): 157-169, 1997.

27. Alexander, H.R., Jr., Bartlett, D.L., Libutti, S.K: Isolated hepatic perfusion: A potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Canc. J. from Sci. Am. 1998 Jan-Feb; 4(1): 2-11 Review PubMed PMID: 9467038.

28. Alexander HR, Bartlett DL, Libutti SK, Fraker, D.L., Moser, T., Rosenberg SA: Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Clin. Oncol. 16: 1479-1489. 1998.

29. Bartlett DL, Buell JF, Fraker DL, Reed E, Lee KB, Figg WD, Venzon DJ, Alexander HR: Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) with TNF and Cisplatin Cancer, 83: 1251-1261, 1998.


30. Alexander, H.R., Fraker, D.L., Norton, J.A., Bartlett, D.L., Tio, L., Benjamin, S.B., Doppman J.L., Goebel, S.U., Serrano, J., Gibril, F., Jensen, R.T. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann. Surg. 228, 228-238, 1998.

31. Alexander, H.R., Brown, C.K., Bartlett, D.L., Libutti, S.K., Figg, W.D., Raje, S., Turner, E. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. Clin.Cancer Res. 4: 2357-2362, 1998.

32. Doppman, J.L., Skarulis, M.C., Chang, R., Alexander, H.R., Bartlett, D.L., Libutti, S.K., Marx, S.J., Spiegel, A.M. Hypocalcemic stimulation and nonselective venous sampling for localizing parathyroid adenomas: Work in Progress. Radiology. 208, 145-151, 1998.

33. Park, B.J., Huang, J., Royalty, D., Libutti, S.K., Skarulis, M.C., Jensen, Fraker, D.L.,Gorden, P., Norton, J.A., Alexander, H.R., Bartlett, D.L. Operative management of islet cell tumors (ICTS) arising in the head of the pancreas. Surgery. 124: 1056-1062, 1998.

34. Libutti, S.K., Choyke, P.L., Bartlett, D.L., Vargas, H.A., Walther, M., Lubensky, I., Glenn, G., Steinberg, S., Linehan, W.M. Alexander, M.D. Pancreatic neuroendocrine tumors associated with von Hippel Lindau: Diagnostic and management recommendations. Surgery. 124: 1153-1159, 1998.

35. Alexander, H.R., Bartlett, D.L., Venzon, D.T., Libutti, S.K., Doppman, J.L., Fraker, D.L., Norton, J.A., Gibril, F., Jensen, R.T. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation and resection for Zollinger-Ellison syndrome (ZES). Surgery. 124: 1160-116, 1998.

36. Cho, H-K., Lush, R.M., Bartlett, D.L., Alexander, H.R., Wu, P.C., Libutti, S.K., Lee, K.B., Venzon, D.J., Bauer, K.S., Reed, E., Figg, W.D. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J. Clin. Pharm. 39: 1-8, 1999.

37. Steller, M.A., Egorin, M.J., Trimble, E.L., Bartlett, D.L., Zuhowski, E.G., Alexander, H.R., Dedrick, R.L. A pilot phase I trial of continuous hyperthermic peritoneal perfusion (CHPP) with high-dose carboplatin (CBDCA) as primary treatment of patients with small volume residual ovarian cancer. Cancer Chemother Pharmacol. 43: 106-114, 1999.

38. Berger, A.D., Libutti, S.K., Bartlett, D.L., Skarulis, M.G., Marx, S.J., Spiegel, A.M., Doppman, J.L., Alexander, H.R. Heterogenous gland size in sporadic multiple gland parathyroid hyperplasia. J. Am. Coll Surg., 188: 382-389, 1998.

39. Puhlmann, M., Gnant, M., Brown, C.K., Alexander, H.R., Bartlett, D.L. Thymidine kinase deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor directed gene therapy. Hum Gene Ther. 10: 649-657, 1998.

40. Park, B.J., Alexander, H.R., Libutti, S.K., Wu, P., Royalty, D., Kranda, K., Bartlett, D.L. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol, 16: 582-590, 1999.

41. Masucci, I.P., Calis, K.A., Bartlett, D.L., Alexander, H.R., Merryman, P.K., Cullinane, A.M., Horne, M.K. Thrombocytopenia after isolated limb or hepatic perfusions with


melphalan: the risk of heparin-induced thrombocytopenia. Ann Surg Oncol, 6: 476-480, 1999

42. Park, B.J., Brown, C.K., Alexander, H.R., Horti, J., Raje, S., Figg, W.D., Bartlett, D.L. Augmentation of melanoma-specific gene expression using a tandem malanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. Hum Gene Ther, 10: 889-898, 1999.

43. Wu, P.C., McCart, J.A., Turner, E., Libutti, S.K., Bartlett, D.L., Alexander, H.R. Isolated organ perfusion does not result in systemic microembolization of tumor cells.. Ann. Surg. Oncol. 6: 658-663, 1999.

44. Gnant, MFX., Puhlmann, M., Alexander Jr, HRA.., Bartlett, DL. Systemic Administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res. 59: 3396-3404, 1999.

45. Riker, A, Bartlett, DL. Pancreaticoduodenectomy for chronic pancreatic in a patient with obstruction of the bile duct, duodenum and portal vein: A case report and review of literature.Hepatogastroenterology, 46: 2005-2010, 1999.

46. Gnant, MFX, Berger, AC., Huang,J., Puhlmann, M., Wu, PC., Merino, MJ., Bartlett, DL., Alexander, HR., Libutti, SK. Sensitization of tumor necrosis factor alpha (TNF ) resistant human melanoma by tumor specific in vivo transfer of the gene encoding for endothelial monocyte activating polypeptide II (EMAP-II) using recombinant vaccinia virus. Cancer Res. 59: 4668-4674, 1999

47. Gnant, MFX, Puhlmann,M., Wu, PC., Merino, MJ., Bartlett, DL., Alexander Jr., HR Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases. Ann. Surg. 230: 352-361, 1999

48. Feldman, AL, Alexander Jr., HR., Bartlett, DL., Fraker, DL, Libutti, SK. Management of extremity recurrence after complete response to isolated limb perfusion (ILP) in patients with melanoma. Ann Surg Oncol. 6: 562-567, 1999

49. Gnant, MFX, Noll, LA., Terrill, Wu, PC., Berger, AC., Nguyen, H.Q., Lans,TE., Flynn, BM., Libutti, SK.., Bartlett, DL., Alexander Jr., HR. Isolated hepatic perfusion for lapine liver metastases - impact of hyperthermia on permeability of tumor neovasculature. Surgery 126: 890-900, 1999.

50. Feldman, A.L., Sharaf, R.N., Skarulis, M.C., Bartlett, D.L., Libutti, S.K., Weinstein, L.S., Marx, S.J., Norton, J.A., Fraker, D.L., Alexander, H.R. Results of heterotopic parathyroid autotransplantation: A 13-year experience. Surgery, 126: 1042-1048, 1999

51. Zeh, H., Choyke, P.S., Alexander, H.R., Bartlett, D.L., Libutti, S.K., Chang, R. Summers, R.M. Gadolinium-enhanced 3D MRA prior to isolated hepatic perfusion for metastases. J Comput Assist Tomogr 23(5): 664-669, 1999.

52. Libutti, S.K., Alexander, H.R., Bartlett, D.L., Sampson, M.L., Ruddel, M.E., Skarulis, M., Marx, S.J., Spiegel, A.M., Simmonds, W., Remaley, A.T. Kinetic analysis of the rapid intraoperative parathyroid hormone assay in patients during operation for hyperparathyroidism. Surgery, 126(6): 1145-1150, 1999.


53. Gnant, M.F., Noll, L.A., Irvine, K.R., Puhlmann, M., Terrill, R.E., Alexander, H.R., Jr., Bartlett, D.L. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. J Natl Cancer Inst. 91(20): 174-1750, 1999.

54. Libutti SK, Bartlett DL, Fraker DL, Alexander HR: Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies .J Am Col Surg, 2000.

55. Alexander, H.R., Libutti, S.K., Bartlett, D.L., Puhlmann, M., Fraker, D.L., Bachenheimer, L.C. A Phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 6 (8); 3062-70; 2000

56. Puhlmann, Brown C, Gnant, M., Huang, J., Libutti, S.K., Alexander HR, Bartlett DL: Vaccinia as a vector for tumor directed gene therapy: Biodistribution of a thymidine kinase deleted mutant. Cancer Gene Ther., 7: 66-73, 2000

57. Bartlett, D.L. Treatment of patients with hepatic metastases. Cancer J of Sci Am. 6: S169-S176, 2000.

58. Feldman, A.L., Restifo, N.P., Alexander, H.R., Bartlett, D.L., Hwu, P., Seth, P., Libutti, S.K. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res. 60: 1503-1506, 2000.

59. Feingold, D.L., Alexander, H.R., Chen, C.C., Libutti, S.K., Shawker, T.H., Simonds, W.F., Marx, S.J., Skarulis, M.C., Doppman, J.L., Schrump, D.S., Bartlett, D.L. Ultrasound and sestamibi scan as the only pre-operative imaging tests in re-operation for parathyroid adenomas. Surgery. 2000 Dec,128(6):1103-9;discussion 1109-10.

60. McCart, J.A., Puhlmann, M., Lee, J., Hu, Y., Libutti, S.K., Alexander, H.R., Bartlett, D.L. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther, 7 (14); 1217-23; 2000.

61. Libutti SK, Choyke PL, Alexander HR, Glenn G, Bartlett DL, Zbar B, Lubensky I, McKee SA, Maher ER, Linehan WM, Walther MM. clinical and genetic analysis of patients with pancreatic nuerendocribne tumors associated with von Hippel-Lindau disease. Surgery. 2000 Dec; 128 (6) : 1022-7; discussion 1027-8 PubMed PMID: 11114638.

62. Hirshberg B, Livi A, Bartlett DL, Libutti SK, Alexander HR, Doppman JL, Skarulis MC, Gorden P. forty-eight-hour fast: the diagnostic test for insulinoma. C Clin Endocrinol Metab. 2000 Sep; 85 (9): 3222-6. PubMed PMID: 10999812.

63. McCart, J.A., Ward, J.M., Lee, J., Hu, Y., Alexander, H.R., Libutti, S.K., Moss, B., Bartlett, D.L., Systemic cancer therapy with a tumor selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001 Dec 15; 61(24):8751-7

64. Feldman, AL, Alexander, HR, Bartlett, DL, Kranda, KC, Miller, MS, Costouros, NG, Choyke, PL, and Libutti, SK. A Prospective Analysis of Plasma Endostatin Levels in Colorectal Cancer Patients with Liver Metastases. Annals of Surgical Oncology, 8(9):741-745, 2001.


65. Hu Y, Lee J, McCart JA, Xu H, Moss B, Alexander HR, Bartlett DL. Yaba-like disease virus: an alternative replication poxvirus vector for cancer gene therapy. J Virol. 2001 Nov;75(21):10300-8

66. Kivlen MH, Bartlett DL, Libutti SK, Skarulis MC, Marx SJ, Simonds WF, Weinstein LS, Jensen RT, McCart JA, Naik AM, Kranda KC, Brennan MF, Norton JA, Fraker DL, Alexander HR.Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery. 2001 Dec:130(6):991-8.

67. Chang E, Alexander HR, Libutti SK, Hurst R, Zhai S, Figg WD, Bartlett DL. Laparoscopic continuous hypthermic pertioneal perfusion. J Am Coll Surg. 2001; 193(2):225-9.

68. Berger AC, Gibril F, Venzon DJ, Doppman JL, Norton JA, Bartlett DL, Libutti SK, Jensen RT, Alexander HR. Prognostic value of initial fasting serum gastrin levels in patients with Zollinger-Ellison syndrome. J Clin Oncol. 2001; 19(12):3051-7.

69. Lans TE, Bartlett DL, Libutti Sk, Gnant MF, Liewehr DJ, Venzon DJ, Turner EM, Alexander HR. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion.Clin Cancer Res. 2001; 7(4):784-90.

70. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresestable hepatic metastases from colorectal cancer. Surgery. 2001; 129(2):176-87.

71. Libutti SK, Alexander HR Jr, Choyke P, Bartlett DL, Bacharach SL, Whatley M, Jousse F, Eckelman WC, Kranda K, Neumann RD, Carrasquillo JA. A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol. 2001; 8(10):779-86.

72. Zogakis TG, Bartlett DL, Libutti SK, Liewehr DJ, Steinberg SM, Fraker DL, Alexander HR. Factors affecting survival after complete response to isolated limb perfusion in patients

73. Zeh,H J, Bartlett, DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Therapy 2002; 9: 1001-1012.

74. Elaraj DM, Remaley AT, Simonds WF, Skarulis MC, Libutti SK, Bartlett DL, Venzon DJ, Marx SJ, Alexander H. Utility of rapid intraoperative parathyroid hormone assay to predict severe postoperative hypocalcemia after reoperation for hyperparathyroidism. Surgery. 2002; 132(6):1028-33; discussion 1033-4.

75. Marcos HB, Libutti SK, Alexander HR, Lubensky IA, Bartlett DL, Walther MM, Linehan WM, Glenn GM, Choyke PL. Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology. 2002; 225(3):751-8.

76. McCart JA, Wang ZH, Xu H, Hu Y, Park B, Alexander HR, Bartlett DL. Development of a melanoma-specific adenovirus. Mol Ther. 2002; 6(4):471-80.


77. Albright SV, McCart JA, Libutti SK, Bartlett DL, Alexander HR, Sampson ML, Ruddel ME, Remaley AT. Rapid measurement of insulin using the Abbott IMx: application to the management of insulinoma. Ann Clin Biochem. 2002; 39(Pt 5):513-5.

78. Alexander HR Jr, Libutti SK, Bartlett DL, Pingpank JF, Kranda K, Helsabeck C, Beresnev T. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer. 2002; 95(4):730-6.

79. Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EN, Gnant MF, Alexander HR.Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood. 2002; 100(4):1334-9.

80. Hirshberg B, Libutti SK, Alexander HR, Bartlett DL, Cochran C, Livi A, Chang R, Shawker T, Skarulis MC, Gorden P. Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure.J Am Coll Surg. 2002; 194(6):761-4.

81. Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, Bartlett D, choyke P, Robey R, Hung E, Steinberg SM, Bates S, Fojo T,. A phase II trial of combination chemotherapy and surgical resection for treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer. 2002. May 1;94(9): 2333-43. PubMed PMID: 12015757.

82. Lublin M, Bartlett DL, Danforth DN, Kauffman H, Gallin JI, Malech HL, Shawker T, Choyke P, Kleiner DE, Schwartzentruber DJ, Chang R, DeCarlo ES, Holland SM. Hepatic abscess in patients with chronic granulomatous disease. Ann Surg. 2002; 235(3):383-91.

83. Alexander HR Jr, Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, Beresneva T. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003; 9(17):6343-9.

84. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003; 21(24):4560-7.

85. Elaraj DM, Skarulis MC, Libutti SK, Norton JA, Bartlett DL, Pingpank JF, Gibril F, Weinstein LS, Jensen RT, Marx SJ, Alexander HR. Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery. 2003; 134(6):858-64; discussion 864-5.

86. Feldman ED, Wu PC, Beresneva T, Helsabeck C, Rodriguez M, Bartlett DL, Libutti SK, Pingpank JF, Alexander HR. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg. 2004; 8(2):200-7.

87. McCart AJ, Mehta N, Scollard D, Reilly RM, Carrasquillo JA, Tang N, Deng H, Miller M, Xu H, Libutti S, Alexander HR, and Bartlett DL. Oncolytic Vaccinia Virus Expressing the Human Somatostatin Receptor SSTR2: Molecular Imaging after Systemic Delivery Using 111In-Pentetreotide. Molecular Therapy. 2004; 10(3): 553.561.


88. Chang E Chalikonda S, Friedl J, Xu H, Phan GQ, Marincola FM, Alexander HR, and Bartlett DL. Targeting Vaccinia to Solid Tumors with Local Hyperthermia. Human Gene Therapy. 2005; 16(4):435-44.

84. Koniaris LG, Staveley-O’Carroll KF, Zeh, HJ, Perez E, Jin XL, Maley WR, Zabari G, Bartlett DL, Khanna A, Franceshi D, Schoeniger LO. Pancreaticoduodenectomy in the Presence of Superior Mesenteric Venous Obstruction. J Gastrointest Surg. 2005; 9(7):915-921. PMID: 16137584

85. Guo, ZS, A. Naik, M. E. O'Malley, P. Popovic, R. Demarco, Y. Hu, X. Yin, S. Yang, H. J. Zeh, B. Moss, M. T. Lotze, and D. L. Bartlett. The Enhanced Tumor Selectivity of an Oncolytic Vaccinia Lacking the Host Range and Anti-Apoptosis Genes SPI-1 and SPI-2. Cancer Res. 2005; 65(21): 9991-8.

86. Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze, MT, Herberman RB. Natural-killer dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther. 2005; 5(10): 1305-15.

87. Farma JM, Pingpank JF, Libutti SK, Bartlett DL, Ohl S, Beresneva T, Alexander HR. Limited Survival in Patients with Carcinomatosis from Foregut Malignancies after Cytoreduction and Continuous Hyperthermic Peritoneal Perfusion. J Gastrointest Surg. 2005; 9(9):1346-1353.

88. Naik AM, Chalikonda S, McCart JA, Xu H, Guo ZS, Langham G, Gardner D, Mocellin S, Lokshin AE, Moss B, Alexander HR, Bartlett DL. Intravenous and isolate limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates. Hum Gene Ther. 2006; 17(1): 31-45.

89. Gruttadauria S, Marsh JW, Bartlett DL, Gridelli B, Marcos A. Ex situ resection techniques and liver autotransplantation: last resource for otherwise unresectable malignancy. Dig Dis Sci. 2005; 50(10): 1829-35.

90. Fecker LF, Geilen CC, Hossini AM, Schwarz C, Fechner H, Bartlett DL, Orfanos CE, Eberle J. Selective induction of apoptosis in melanoma cells by tryrosinase promoter-controlled CD95 ligand overexpression. J Invest Dermatol. 2005; 124(1):221-8.

91. Maheshwari V, Tsung A, Lin Y, Zeh HJ 3rd, Finkelstein SD, Bartlett DL. Analysis of loss of heterozygosity for tumor-suppressor genes can accurately classify and predict the clinical behavior of mucinous tumors arising from the appendix. In: Ann Surg Oncol. 2006; 13(12):1610-6.

92. Bartlett DL, Berlin J, Lauwers GY, Messersmith WA, Petrelli NJ, Venook AP. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006 13(10): 1284-92.

93. Thorne SH, Bartlett DL, Kirn DH. The use of oncolytic vaccinia viruses in the treatment

of cancer: a new role for an old ally? Curr Gene Ther. 2005; 5(4):429-43. 94. Alexander HR Jr., Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresneva T.

Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol. 2005; 12(2):138-44.


95. Guo ZS, Bartlett DL. Vaccinia as a vector for gene delivery. Expert Opin Biol Ther. 2004; 4(6): 901-17.

96. Popovic PJ, DeMarco R, Lotze MT, Winnikoff SE, Bartlett DL, Krieg AM, Guo ZS, Brown CK, Tracey HJ, Zeh HJ. High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol. 2006; 177(12):

8701-7.

97. Zeh HJ, Winikoff S, Landsittel DP, Gorelik E, Marrangoni AM, Velikokhatnaya L, Winans MT, Lee K, Moser A, Bartlett D, Lotze MT, Siegfried JM, Whitcomb D, Papacristou G, Slivka A, Bigbee WL, Lokshin AE. Multianalyte profiling of serum cytokines for detection of pancreatic cancer. Cancer Biomark. 2005;1(6):259-69. Erratum in: Cancer Biomark. 2006;2(3-4):175. Papacristou, G [added]. PubMed PMID:17192050

98. Yang S, Guo ZS, O’Malley ME, Yin X, Zeh HJ, Bartlett DL. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Gene Ther. 2007; 14(8):638-47.

99. Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S,

Winikoff S, Brown CK, Bartlett DL, Zeh HJ 3rd. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother. 2007 Sep;30(6):596-606. PubMed PMID: 17667523.

100. Chalikonda S, Kivlen MH, O'Malley ME, Eric Dong XD, McCart JA, Gorry MC, Yin XY, Brown CK, Zeh HJ 3rd, Guo ZS, Bartlett DL. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther. 2008; 15(2):115-25.

101. Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, Wang Y, Bell J, Kirn DH. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest. 2007; 117(11):3350-8.

102. Bartlett DL, Washington ML, Bryant A, Thurston N, Perfili CA. Cost savings associated with using immunization information systems for Vaccines for Children administrative tasks. J Public Health Manag Pract. 2007; 13(6): 559-66.

103. Hu W,Davis JJ, Zhu H, Dong F, Guo W, Ang J, Peng H, Guo ZS, Bartlett DL, Swisher SG, Fang B. Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy. Cancer Biol Ther. 2007; 6(11):1773-9.

104. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, Debree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L,

http://www.ncbi.nlm.nih.gov/pubmed/18084242?ordinalpos=14&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum











Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007 Jan; 14 (1) :128-33. Epub 2006 Oct 28. PubMed PMOD: 17072675.

104. Gamblin TC, Egorin MJ, Zuhowski EG, Lagattuta TF, Herscher LL, Russo A, Libutti SK, Alexander HR, Dedrick RL, Bartlett DL. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. Cancer Chemother Pharmacol. 2008; 62(4):647-53.

105. Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, Seidel G, Shutack Y, Yuldasheva N, Eugeni M, Bartlett DL, Glenn GM, Middelton L, Linehan WM, Libutti SK. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery. 2007 Dec;142(6):814-8; discussion 818.e1-2. Erratum in: Surgery. 2008 Feb;143(2):302.

106. Deraco M, Bartlett D, Kusamura S, Baratti D. Consensus statement on peritoneal mesothelioma. J Surg Oncol. 2008 Sep 15;98(4):268-72. Review. PubMed PMID: 18726890.

107. Verzaro R, Zeh H, Bartlett D. A safe and fast technique for isolated hepatic perfusion. J Surg Oncol. 2008 Oct 1;98(5):393-6. PubMed PMID: 18646044. 108. Bartlett DL HIPEC: The complexities of clinical trials. Ann Surg Oncol. 2008; 15(5):1277-9. 109. Chalikonda S, Kivlen MH, O'Malley ME, Eric Dong XD, McCart JA, Gorry MC, Yin XY, Brown CK, Zeh HJ 3rd, Guo ZS, Bartlett DL. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther. 2008;15(2):115-25. 110. Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holtzman MP, Zeh HJ, Bartlett DL. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol. 2008;15(3):754-63. 111. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: Molecular targets in tumor selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta. 2008; 1785: 217-231.







http://www.ncbi.nlm.nih.gov/pubmed/18084242?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum





112. Hu W, Hofstetter W, Guo W, Li H, Pataer A, Peng HH, Guo ZS, Bartlett DL, Lin A, Swisher SG, Fang B. JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase. Cancer Gene Ther. 2008;15(9):616-24. 113. Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation.Cancer Res. 2008; 68(14):5972-8. 114. Powell AC, Stratakis CA, Patronas NJ, Steinberg SM, Batista D, Alexander HR, Pingpank JF, Keil M, Bartlett DL, Libutti SK. Operative management of Cushing syndrome secondary to micronodular adrenal hyperplasia. Surgery. 2008; 143(6):750-8. 115. Franko J, Krasinskas AM, Nikiforova MN, Zarnescu NO, Lee KK, Hughes SJ, Bartlett DL, Zeh HJ 3rd, Moser AJ. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. J. Gastrointest Surg. 2008;12(10):1664-72; discussion 1672-3. 116. Guo ZS, Li Q, Bartlett DL, Yang JY, Fang B. Gene transfer: the challenge of regulated gene expression. Trends Mol Med. 2008;14(9): 410-8. 117. Franko J, Gusani NJ, Holtzman MP, Ahrendt SA, Jones HL, Zeh HJ 3rd, Bartlett DL. Multivisceral Resection Does Not Affect Morbidity and Survival After Cytoreductive Surgery and Chemoperfusion for Carcinomatosis from Colorectal Cancer. Ann Surg Oncol. 2008; 15(11):3065-72. 118. Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, Geller BA, Schmotzer A, Potter DP, Whiteside T, Finn OJ, Ramanathan RK. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008;6(B):955-964. PubMed PMID: 19129927; PubMed Central PMCID: PMC2614325 119. Cho SW, Marsh JW, Geller DA, Holtzman M, Zeh H 3rd, Bartlett DL, Gamblin TC. Surgical management of leiomyosarcoma of the inferior vena cava. J Gastrointest Surg. 2008; 12(12):2141-8. 120. Powell AC, Alexander HR, Pingpank JF, Steinberg SM, Skarulis M, Bartlett DL, Agarwal S, Cochran C, Seidel G, Fraker D, Hughes MS, Jensen RT, Marx SJ, Libutti SK. The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. Surgery. 2008;144(6):878-83; discussion 883-4. 121. Herbert J. Zeh III, MD, Charles K. Brown, MD, PhD, Matthew P. Holtzman, MD, Merrill J. Egorin, MD, Julianne L. Holleran, BS, Douglas M. Potter, PhD, and Bartlett DL. A














Phase I Study of Hyperthermic Isolated Hepatic Perfusion with oxaliplatin in the treatment of uresectable liver metastases from colorectal cancer. Ann Surg Oncol. 2009; 16(2):385-94. Epub 2008 Nov 25. PubMed PMID: 19034580. 122. Chang JF, Chen PJ, Sze DY, Teid T, Bartlett, D, Kirn DH, Liu TC. Oncolytic virotherapy for advanced liver tumors. J Cell Mol Med. 2009; 13(7) 1238-1247. 123. Bao P, Bartlett DL. Surgical techniques in visceral resection and peritonectomy procedures. Cancer J. 2009; 15: 204-211. 124. Alexander HR Jr, Bartlett DL, Libutti SK, Pingpank JF, Fraker DL, Royal R, Steinberg SM, Helsabeck CB, Beresneva TH. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol. 2009; 16(7):1852-9. 125. Bartlett DL. Intrahepatic Cholangiocarcinoma: a worthy challenge Cancer J. 2009; 15 (3): 255-25. 126. Li Q, Bartlett DL, Gorry MC, O'Malley ME, Guo ZS. Three epigenetic drugs up-

regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms. Mol Pharmacol. 2009; 76: 1072-1081.

127. Alexander HR Jr, Bartlett DL, Libutti SK, Pingpank JF, Fraker DL, Royal R, Steinberg SM, Helsabeck CB, Beresneva TH. Analysis of factors associated with outcome in undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol. 2009; 16(7):1852-9. 128. Alexander HR Jr, Fraker DL, Bartlett DL, Libutti SK, Steinberg SM, Soriano P, Beresnev T. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol. 2010 Jan 1;28(1):114-8. Epub 2009 Nov 9. PubMed PMID: 19901107; PubMed Central PMCID: PMC2799229. 129. Powell AC, Alexander HR, Chang R, Marx SJ, Skarulis M, Pingpank JF, Bartlett DL, Hughes M, Weinstein LS, Simonds WF, Collins MF, Shawker T, Chen CC, Reynolds J, Cochran C, Steinberg SM, Libutti SK. Reoperation for parathyroid adenoma: a contemporary experience. Surgery. 2009 Dec;146(6):1144-55. PubMed PMID: 19958942. 130. Alyssa M Krasinskas, David L Bartlett, Kathleen Cieplyand Sanja Dacic. CDKN2A and MTAP Deletions in Peritoneal Mesotheliomas are Correlated with Loss of p16 Protein Expression and Poor Survival. Modern Pathology. 2010 15 January. 131. Helm CW, Richard SD, Pan J, Bartlett D, Goodman MD, Hoefer R, Lentz SS, Levine EA, Loggie BW, Metzinger DS, Miller B, Parker L, Spellman JE, Sugarbaker PH, Edwards RP, Rai SN. Hyperthermic intraperitoneal chemotherapy in ovarian











cancer: first report of the HYPER-O registry. Int J Gynecol Cancer. 2010 Jan;20(1):61-9. PubMed PMID: 20130504. 132. Ziauddin MF, Guo ZS, O'Malley ME, Austin F, Popovic PJ, Kavanagh MA, Li J, Sathaiah M, Thirunavukarasu P, Fang B, Lee YJ, Bartlett DL. TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Ther. 2010 Feb 25. 133. Song JJ, Kim JH, Sun BK, Alcala MA Jr, Bartlett DL, Lee YJ. c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment. Cell Signal. 2010 Mar;22(3):377-85. 134. Mavanur A, Parini V, O’Malley M, Nikiforova M, Bartlett DL, and Davison JM. Establishment and characterization of murine xenograft model of appendiceal mucinous adenocarcinoma. Int J Exp Path. (2010) 135. Varghese S, Xu H, Bartlett D, Hughes M, Pingpank JF, Beresnev T, Alexander HR Jr. Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma. Ann Surg Oncol. 2010 Jul;17(7):1870-7. 136. Idrees K, Bartlett DL. Robotic Liver Surgery. Surg Clin N Am 90 (2010) 761–774. 137. Thirunavukarasu P, Sathaiah M, Singla S, Sukumar S, Karunamurthy A, Pragatheeshwar KD, Lee KK, Zeh H 3rd, Kane KM, Bartlett DL. Medullary carcinoma of the large intestine: A population based analysis. Int J Oncol. 2010 Oct;37(4):901-7. 138. Guo ZS, Parimi V, O'Malley ME, Thirunavukarasu P, Sathaiah M, Austin F, Bartlett DL. The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host. Gene Ther. 2010 Aug 12. 139. Krasinskas AM, Bartlett DL, Cieply K, Dacic S. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol. 2010 Apr;23(4):531-8. 140. Thirunavukarasu P, Sathaiah M, Sukumar S, Bartels CJ, Zeh H 3rd, Lee KK, Bartlett DL. Meckel's Diverticulum-A High-Risk Region for Malignancy in the Ileum: Insights From a Population-Based Epidemiological Study and Implications in Surgical Management. Ann Surg. 2010 Dec 3. [Epub ahead of print] Ann Surg. 2011 Feb;253(2):223-30. 141. Bao PQ, Ramanathan RK, Krasinkas A, Bahary N, Lembersky BC, Bartlett DL, Hughes SJ, Lee KK, Moser AJ, Zeh HJ 3rd. Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer. Ann Surg Oncol. 2011 Apr;18(4):1122-9.

http://www.ncbi.nlm.nih.gov/pubmed/20182517?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

http://www.ncbi.nlm.nih.gov/pubmed/20182517?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Thirunavukarasu%20P%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sathaiah%20M%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Singla%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sukumar%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Karunamurthy%20A%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pragatheeshwar%20KD%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pragatheeshwar%20KD%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lee%20KK%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Zeh%20H%203rd%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kane%20KM%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bartlett%20DL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed/20703311









142. Zureikat AH, Nguyen KT, Bartlett DL, Zeh HJ, Moser AJ. Robotic-Assisted Major Pancreatic Resection and Reconstruction. Arch Surg. 256-61, 2010 Nov 15. 143. Alcala MA, Kwan SY, Shade CM, Lang M, Uh H, Wang M, Weber SG, Bartlett DL, Petoud S, Lee YJ. Luminescence targeting and imaging using a nanoscale generation 3 dendrimer in an in vivo colorectal metastatic rat model. Nanomedicine. 7(3):249-58. 2011 Jun. 144. Thirunavukarasu P, Sathaiah M, Singla S, Sukumar S, Karunamurthy A, Pragatheeshwar KD, Lee KK, Zeh H 3rd, Kane KM, Bartlett DL. Medullary carcinoma of the large intestine: a population based analysis. Int J Oncol. 2010 Oct;37(4):901-7. 145. Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ 3rd. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010 Aug 15;116(16):3756-62. 146. Alcala MA Jr, Park K, Yoo J, Lee DH, Park BH, Lee BC, Bartlett DL, Lee YJ. Effect of hyperthermia in combination with TRAIL on the JNK-Bim signal transduction pathway and growth of xenograft tumors. J Cell Biochem. 2010 Aug 1;110(5):1073-81. 147. Colville H, Dzadony R, Kemp R, Stewart S, Zeh HJ 3rd, Bartlett DL, Holleran J, Schombert K, Kosovec JE, Egorin MJ, Beumer JH. In vitro circuit stability of 5- fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion. J Extra Corpor Technol. 2010 Mar;42(1):75-9. 148. Zureikat AH, Nguyen KT, Bartlett DL, Zeh HJ, Moser AJ. Robotic-assisted major pancreatic resection and reconstruction. Arch Surg. 2011 Mar;146(3):256-61. 149. Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, Thorne SH, Bartlett DL. Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer. Mol Ther. 2011 Jan 25. 150. Varghese S, Chen Z, Bartlett DL, Pingpank JF, Libutti SK, Steinberg SM, Wunderlich J, Alexander HR Jr. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer. 2011 Jan 15;117(2):361-71. 151. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS. Induction of CD8+ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With {alpha}-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma. J Clin Oncol. 2011 Jan 20;29(3):330-6.


























152. Thirunavukarasu P, Sukumar S, Sathaiah M, Mahan M, Pragatheeshwar, KD, Pingpank JF, Zeh H 3rd, Bartels CJ, Lee KK, Bartlett DL. C-stage in Colon Cancer: Implications in Carcinoembryonic Antigen Biomarker in Staging, Prognosis and Management . J Natl Cancer Inst. 2011 Apr 20;103(8):689-97. 153. Nguyen KT, Zureikat AH, Chalikonda S, Bartlett DL, Moser AJ, Zeh HJ. Technical aspects of robotic-assisted pancreaticoduodenectomy (RAPD). J Gastrointest Surg. 2011 May;15(5):870-5. 154. Li Q, O'Malley ME, Bartlett DL, Guo ZS. Homeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growth. Mol Cancer. 2011 May 24;10:63. 155. Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL. Dendritic cells in cancer immunotherapy: vaccines or autologous Transplants? Immunol Res. 2011 Aug;50(2-3):235-47. 156. Xiao H, Peng Y, Hong Y, Liu Y, Guo ZS, Bartlett DL, Fu N, He Y. Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma. J Immunol. 2011 Aug 15;187(4):1788-96. 157. Kitisin K, Packiam V, Bartlett DL, Tsung A. A current update on the evolution of robotic liver surgery. Minerva Chir. 2011 Aug;66(4):281-93. 158. Alcala MA, Shade CM, Uh H, Kwan SY, Bischof M, Thompson ZP, Gogick KA, Meier AR, Strein TG, Bartlett DL, Modzelewski RA, Lee YJ, Petoud S, Brown CK. Preferential accumulation within tumors and in vivo imaging by functionalized luminescent dendrimer lanthanide complexes. Biomaterials. 2011 Dec;32(35):9343-52. Epub 2011 Sep 16. 159. Zeh HJ, Zureikat AH, Secrest A, Dauoudi M, Bartlett D, Moser AJ. Outcomes After Robot-Assisted Pancreaticoduodenectomy for Periampullary Lesions. Ann Surg Oncol. 2011 10434-011-2045-0Sep 24. 160. Zeh HJ 3rd, Bartlett DL, Moser AJ. Robotic-assisted major pancreatic resection. Adv Surg. 2011;45:323-40. Review. 161. Thirunavukarasu P, Sukumar S, Bartlett D. Risk of Cancer in Meckel's Diverticulum. Ann Surg. 2011 Dec;254(6):1080. 162. Sathaiah M, Thirunavukkarasu P, O'Malley ME, Kavanagh MA, Ravindranathan R, Austin F, Guo ZS, Bartlett DL. Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer. Cancer Gene Ther. Mar;19(3):192-201, 2012. 164. Boone BA, Wagner P, Ganchuk E, Evans L, Zeh HJ, Bartlett DL, Holtzman MP.


Single-incision laparoscopic right colectomy in an unselected patient population. Surg Endosc. Jun;26(6):1595-601, 2012. 165. John, L. B., Howland, L. J.,* Flynn, J. K., West, A. C., Devaud, C., Duong, C. M., Stewart, T. J., Westwood, J. A., Guo, Z. S., Bartlett, D. L., Smyth, M. J., Kershaw, M. H., Darcy, P. K. Oncolytic virus and anti-4-1BB combination therapy elicits strong anti-tumor immunity against established cancer. Cancer Res. 2012 Apr 1;72(7):1651-60. 166. Gamblin TC, Alexander HR, Edwards R, Bartlett DL. Concepts of Regional Therapies for Advanced Malignancy. Ann Surg Oncol. 2012 May;19(5):1371-2. 167. Choudry HA, Mavanur A, O'Malley ME, Zeh HJ, Sheng Guo Z, Bartlett DL. Chronic Anti-inflammatory Drug Therapy Inhibits Gel-Forming Mucin Production in a Murine Xenograft Model of Human Pseudomyxoma Peritonei. Ann Surg Oncol. 19(5):1402-9 (2012), [Epub ahead of print] PubMed PMID: 22302271. 168. Austin F, Mavanur A, Sathaiah M, Steel J, Lenzner D, Ramalingam L, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA. Aggressive Management of Peritoneal Carcinomatosis from Mucinous Appendiceal Neoplasms. Ann Surg Oncol. 2012 Feb 3. 2012 May;19(5):1386-93. [Epub ahead of print] PubMed PMID: 22302270. 169. Bartlett DL, Chu E. Can metastatic colorectal cancer be cured? Oncology (Williston Park). 2012 Mar;26(3):266-75. Review. PMID: 22545311 170. Cole KL, Choudry HA, Jones HL, Goodell PP, Bartlett DL. Critical role of hyperthermic intraperitoneal chemoperfusion in the treatment of a patient with Pseudomyxoma peritonei. J Surg Oncol. 2012 Sep 15;106(4):513-6. [Epub ahead of print.] PMID: 22396067 [PubMed - as supplied by publisher.] 171. Boone BA, Bartlett DL, Zureikat AH. Isolated hepatic perfusion for the treatment of liver metastases. Curr Probl Cancer. 2012 Mar-Apr;36(2):27-76. PMID: 22464447. 172. John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, Stewart TJ, Westwood JA, Guo ZS, Bartlett DL, Smyth MJ, Kershaw MH, Darcy PK. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res. 2012 Apr 1;72(7):1651-60. Epub 2012 Feb 7. PMID: 22315352 [PubMed - indexed for MEDLINE.] 173. Boone BA, Bartlett DL, Zureikat AH; Isolated Hepatic Perfusion for the Treatment of Liver Metastases. Current Problems in Cancer, Volume 36, Issue 2, March–April 2012, Pages 27–76. 174. Gamblin T, Alexander H, Edwards R, Bartlett DL. Concepts of regional therapies for advanced malignancies. Ann Surg Oncol. 2012 May;19(5):1371-2. PMID: 22302272

http://pubget.com/search?q=issn%3A1068-9265+vol%3A19+issue%3A5&from=22302271


http://www.sciencedirect.com/science/journal/01470272

http://www.sciencedirect.com/science/journal/01470272/36/2


175. Choudry HA, O'Malley ME, Guo ZS, Zeh HJ, Bartlett DL. Mucin as a therapeutic target in pseudomyxoma peritonei. J Surg Oncol. 2012 Dec;106(7):911-72012 May 14. doi: 10.1002/jso.23146. PMID: 22585683. 176. Winer J, Can MF, Bartlett DL, Zeh HJ, Zureikat AH. The current state of robotic- assisted pancreatic surgery. Nat Rev Gastroenterol Hepatol. 2012 Aug;9(8):468-76. doi: 10.1038/nrgastro.2012.120. Epub 2012 Jun 26. PMID: 22733352. 177. Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, Luong TM, Reinhart TA, Bartlett DL, Kalinski P. NF-κB Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells. Cancer Res. 2012 Aug 1;72(15):3735-43. Epub 2012 May 16. PMID: 22593190. 178. Minimally invasive liver resection: robotic versus laparoscopic left lateral sectionectomy. Packiam V, Bartlett DL, Tohme S, Reddy S, Marsh JW, Geller DA, Tsung A. J Gastrointest Surg. 2012 Dec;16(12):2233-8. doi: 10.1007/s11605-012-2040-1. Epub 2012 Oct 5. 179. Wagner PL, Austin F, Sathaiah M, Magge D, Maduekwe U, Ramalingam L, Jones HL, Holtzman MP, Ahrendt SA, Zureikat AH, Pingpank JF, Zeh HJ 3rd, Bartlett DL, Choudry HA. Significance of Serum Tumor Marker Levels in Peritoneal Carcinomatosis of Appendiceal Origin. 2012 Sep 1. Ann Surg Oncol. 2013 Feb;20(2):506-14. [Epub ahead of print] PMID:22941175.

180. Clark Gamblin T, Richard Alexander H, Edwards R, Bartlett DL. Regional Therapies for Cancer. Ann Surg Oncol. 2013 Mar 2. [Epub ahead of print] PMID:23456388.

181. Wagner PL, Austin F, Maduekwe U, Mavanur A, Ramalingam L, Jones HL, Holtzman MP, Ahrendt SA, Zureikat AH, Pingpank JF, Zeh HJ, Bartlett DL, Choudry HA. Extensive Cytoreductive Surgery for Appendiceal Carcinomatosis: Morbidity, Mortality, and Survival. Ann Surg Oncol. 2013 Mar 2. [Epub ahead of print] PMID: 23456385.

182. Thirunavukarasu P, Sathaiah M, Gorry MC, O'Malley ME, Ravindranathan R, Austin F, Thorne SH, Guo ZS, Bartlett DL . A Rationally Designed A34R Mutant Oncolytic Poxvirus: Improved Efficacy in Peritoneal Carcinomatosis. Mol Ther. 2013 Feb 26. doi: 10.1038/mt.2013.27. [Epub ahead of print] PMID: 23439499.

183. Baumgartner JM, Ahrendt SA, Pingpank JF, Holtzman MP, Ramalingam L, Jones HL, Zureikat AH, Zeh HJ 3rd, Bartlett DL, Choudry HA. Aggressive locoregional management of recurrent peritoneal sarcomatosis. J Surg Oncol. 2013 Mar;107(4):329- 34. doi: 10.1002/jso.23232. Epub 2013 Feb 5. PMID: 23386388.

184. Guo ZS, Liu Z, Bartlett DL, Tang D, Lotze MT. Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res. 2013;3(1):1-20. Epub 2013 Jan 18.PMID: 23359863.




















185. Abood GJ, Can MF, Daouadi M, Huss HT, Steve JY, Ramalingam L, Stang M, Bartlett DL, Zeh HJ 3rd, Moser AJ. Robotic-Assisted Minimally Invasive Central Pancreatectomy: Technique and Outcomes. J Gastrointest Surg. 2013 Jan 17. [Epub ahead of print] PMID: 23325340.

186. Li J, O'Malley M, Sampath P, Kalinski P, Bartlett DL, Thorne SH. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. Neoplasia. 2012 Dec;14(12):1115-21. PMID: 23308044.

187. Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I. A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol. 2013 Feb;20(2):555-61. doi: 10.1245/s10434-012-2651-5. Epub 2012 Dec 12. PMID: 23233234.

188. Sampath P, Li J, Hou W, Chen H, Bartlett DL, Thorne SH. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther. 2013 Mar;21(3):620-8. doi: 10.1038/mt.2012.257. Epub 2012 Dec 11. PMID: 23229093.

189. Magge D, Zureikat AH, Bartlett DL, Holtzman MP, Choudry HA, Beumer JH, Pingpank JF, Holleran JL, Strychor S, Cunningham DE, Jones HL, Zeh HJ 3rd. A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer. Ann Surg Oncol. 2013 Jul;20(7):2180-7. doi: 10.1245/s10434-013-2960-3. Epub 2013 Apr 11. PMID: 23575907

190. Boone BA, Zeh HJ, Mock BK, Johnson PJ, Dvorchik I, Lee K, Moser AJ, Bartlett DL,

Marsh JW. Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma. HPB (Oxford). 2013 Apr 22. doi: 10.1111/hpb.12119. [Epub ahead of print] PMID:23601033

191. Xiao H, Peng Y, Hong Y, Huang L, Guo ZS, Bartlett DL, Fu N, Munn DH, Mellor A,

He Y. Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization. J Immunol. 2013 Jun 1;190(11):5866-73. doi: 10.4049/jimmunol.1203470. Epub 2013 Apr 22. PMID: 23610140

192. Magge D, Guo ZS, O'Malley ME, Francis L, Ravindranathan R, Bartlett DL.

Inhibitors of C5 complement enhance vaccinia virus oncolysis. Cancer Gene Ther. 2013 Jun;20(6):342-50. doi: 10.1038/cgt.2013.26. Epub 2013 May 10. PMID: 23661042

193. Zureikat AH, Moser AJ, Boone BA, Bartlett DL, Zenati M, Zeh HJ 3rd. 250 robotic pancreatic resections: safety and feasibility.




















Ann Surg. 2013 Oct;258(4):554-9; discussion 559-62. doi: 10.1097/SLA.0b013e3182a4e87c. PMID: 24002300

194. Hong Y, Peng Y, Guo SZ, Guevara-Patino J, Pang J, Butterfield LH, Mivechi N, Munn

DH, Bartlett DL, He Y. Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology. 2013 Oct 12. doi: 10.1002/hep.26893. [Epub ahead of print] PMID: 24122861

195. Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed

oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther. 2013 Oct 17. doi: 10.1038/mt.2013.240. [Epub ahead of print] PMID: 24135899.

196. Howell GM, Carty SE, Armstrong MJ, Stang MT, McCoy KL, Bartlett DL, Yip L.

Outcome and prognostic factors after adrenalectomy for patients with distant adrenal metastasis. Ann Surg Oncol. 2013 Oct;20(11):3491-6. doi: 10.1245/s10434-013-3050-2. Epub 2013 Jun 21. PMID:23793361.

197. Magge D, Choudry HA, Zeh HJ 3rd, Cunningham DE, Steel J, Holtzman MP, Jones HL,

Pingpank JF, Bartlett DL, Zureikat AH. Outcome Analysis of a Decade-Long Experience of Isolated Hepatic Perfusion for Unresectable Liver Metastases at a Single Institution. Ann Surg. 2013 Oct 28. [Epub ahead of print] PMID: 24169176

198. Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer. 2013 Sep 11;12(1):103. [Epub ahead of print] 199. Tsung A, Geller DA, Sukato DC, Sabbaghian S, Tohme S, Steel J, Marsh W, Reddy SK, Bartlett DL. Robotic Versus Laproscopic Hepatectomy: A Matched Comparison. Ann Surg. 2013 Sep 16. [Epub ahead of print] 200. Van Buren G 2nd, Ramanathan RK, Krasinskas AM, Smith RP, Abood GJ, Bahary N,

Lembersky BC, Shuai Y, Potter DM, Bartlett DL, Zureikat AH, Zeh HJ, James Moser A. Phase II Study of Induction Fixed-Dose Rate Gemcitabine and Bevacizumab Followed by 30 Gy Radiotherapy as Preoperative Treatment for Potentially Resectable Pancreatic Adenocarcinoma. Ann Surg Oncol. 2013 Nov;20(12):3787-93. doi: 10.1245/s10434-013-3161-9. Epub 2013 Aug 1. PMID: 23904005

201. Kang R, Zhang Q, Hou W, Yan Z, Chen R, Bonaroti J, Bansal P, Billiar TR, Tsung A,

Wang Q, Bartlett DL, Whitcomb DC, Chang EB, Zhu X, Wang H, Lu B, Tracey KJ, Cao L, Fan XG, Lotze MT, Zeh HJ 3rd, Tang D. Intracellular Hmgb1 Inhibits Inflammatory Nucleosome Release and Limits Acute Pancreatitis in Mice.Gastroenterology. 2013 Dec 17. pii: S0016-5085(13)01799-X. doi: 10.1053/j.gastro.2013.12.015. [Epub ahead of print] PMID:24361123














202. Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA. Malignant Peritoneal Mesothelioma: Prognostic Factors and Oncologic Outcome Analysis. Ann Surg Oncol. 2013 Dec 10. [Epub ahead of print] PMID:24322529.

203. Wong JL, Muthuswamy R, Bartlett DL, Kalinski P. IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients. Oncoimmunology. 2013 Sep 1;2(9):e26245. Epub 2013 Sep 12. PMID:24228233.

204. Winer J, Zenati M, Ramalingam L, Jones H, Zureikat A, Holtzman M, Lee K, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA. Impact of Aggressive Histology and Location of Primary Tumor on the Efficacy of Surgical Therapy for Peritoneal Carcinomatosis of Colorectal Origin.Ann Surg Oncol. 2013 Nov 8. [Epub ahead of print] PMID:24201745.

205. Magge D, Zenati M, Mavanur A, Winer J, Ramalingam L, Jones H, Zureikat A, Holtzman M, Lee K, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA. Aggressive Locoregional Surgical Therapy for Gastric Peritoneal Carcinomatosis. Ann Surg Oncol. 2013 Nov 7. [Epub ahead of print] PMID:24197761.

206. Intracellular Hmgb1 Inhibits Inflammatory Nucleosome Release and Limits Acute Pancreatitis in Mice. Kang R, Zhang Q, Hou W, Yan Z, Chen R, Bonaroti J, Bansal P, Billiar TR, Tsung A, Wang Q, Bartlett DL, Whitcomb DC, Chang EB, Zhu X, Wang H, Lu B, Tracey KJ, Cao L, Fan XG, Lotze MT, Zeh HJ 3rd, Tang D. Gastroenterology. 2013 Dec 17. pii: S0016-5085(13)01799-X. doi: 10.1053/j.gastro.2013.12.015. [Epub ahead of print] PMID:24361123

207. Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death. Kim SY, Song X, Zhang L, Bartlett DL, Lee YJ.

Biochem Pharmacol. 2014 Jan 31. pii: S0006-2952(14)00066-5. doi: 10.1016/j.bcp.2014.01.027. [Epub ahead of print] 2014 Mar 15;88(2):178-88

PMID: 24486574 [PubMed - as supplied by publisher]

208. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA.Ann Surg Oncol. 2014 Apr;21(4):1159-65. doi: 10.1245/s10434-013-3358-y. Epub 2013 Dec 10. PMID:24322529[PubMed - in process].


209. Guo ZS, Liu Z, Bartlett DL. Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Front Oncol. 2014 Apr 10;4:74. eCollection 2014. Review. PMID: 24782985

Edited Books

1. Bartlett DL, Thirunuvakarasu P, Neal M: Surgical Oncology: Fundamentals, Evidence-based Approaches and New Technology, Jaypee Brothers Medical Publishers, Ltd. New Delhi, India. January 2011.

Invited Chapters/Articles:

1. Bartlett DL, Charland SL, Torosian MH: Glucose metabolism and hormone treatment in cancer cachexia. Surgical Forum 42:14-16, 1991.

2. Bartlett DL: Biology of Cancer. In: Essentials of Basic Science in Surgery. Edited by S

Fishman and E Savage. Lippincott, Philadelphia, Pa., 1992.

3. Charland SL, Bartlett DL, Davis R, Torosian MH: Effect of protein-calorie malnutrition on methotrexate pharmacokinetics. JPEN 18(1):45-49, 1994

4. Bartlett DL: Somatostatin. In: Protein and Amino Acid Metabolism in Cancer Cachexia.

Edited by MF Brennan and P Pisters. R.G. Landes Company, Georgetown, Tx., 1996.

5. Bartlett DL, Schwartz LH, Klimstra D, Blumgart LH: Diagnosis and treatment of focal nodular hyperplasia J Hep Bil Pancr Surg. 3: 111-121, 1996.

6. Ma G, Turner E, Jaskowiak N, Sarraf P, Bartlett DL, Fraker D, Alexander HR: Obese gene

expression is acutely regulated by tumor necrosis factor during sublethal endotoxemia in mice. Surg Forum. 47: 17-20, 1996.

7. Bartlett DL: Growth hormone in the Oncology Patient. In: Growth Hormone in Critical

Illness. Edited by MH Torosian. R.G. Landes Company, Georgetown, Tx., 1996.

8. Bartlett DL: Tumours of the Gallbladder. In: Surgery of the Liver and Biliary Tract. Edited by LH Blumgart and Y Fong. Churchill Livingstone, London. 1996. Section 8; Ch.67.

9. Alexander HR, Bartlett DL, Fraker DL, Libutti SK: Regional Treatment Strategies for

Unresectable Primary or Metastatic Cancer Confined to the Liver. In: UPDATES: Principles and Practice of Oncology. 10(8) Edited by SA Rosenberg. Lippincott-Raven, Philadelphia August, 1996.


10. Brown C, Park B, Alexander HR, Bartlett DL: High Level Tissue-Specific Gene Expression in Melanoma Cells with T7 RNA Polymerase Transcriptional Amplification. Surgical Forum. 811-814, 1997.

11. Zeh, H.J., Bartlett, D.L. Sarcoma. In: Current Cancer Therapeutics,. 3rd Edition, M.T.

Lotze, Ed. Current Medicine, Philadelphia, PA 1998.

12. Bartlett DL, Fuller B, Fojo A: Adrenal glands. In: Integrated Cancer Management: Surgery, Medical Oncology, and Radiation Therapy. Edited by M.H. Torosian. Marcel Dekker, Inc., New York, NY. Ch. 12, pp 294-321, 1999.

13. Bartlett DL, McCart JA. Suicide Gene Therapy, In: Biologic Therapy of Cancer, 3rd

edition, Edited by Steven Rosenberg, MD. Lippincott, Williams & Wilkins. Philadelphia, PA.. 2000. pp 781 – 796.

14. Bartlett, DL, Fong, Y. Tumors of the gallbladder, In: Surgery of the Liver and Biliary Tract.

Edited by LH Blumgart and Y. Fong. Churchill Livingstone, London. 2000. pp 993 – 1016.

15. Bartlett DL. Gallbladder cancer. Semin Surg Oncol. 2000 Sep-Oct;19 (2): 145-55. Review

PubMed PMID 11126379.

16. Alexander, H.R., Bartlett, DL, Libutti, SK. NCI experience with regional therapy for unresectable primary and metastatic cancer of the liver or peritoneal cavity. Regional Chemotherapy. Edited by: M. Markham. Humana Press, Inc., Totowa, NJ, 2000.

17. Alexander, H.R., Bartlett, D.L., Libutti, S.K. National Cancer Institute experience with

regional therapy for unresectable primary and metastatic cancer of the liver of peritoneal cavity. In. Current Clinical Oncology: Regional Chemotherapy: Clinical Research and Practice. Ed. Markman, M. Humana Press Inc., Totoway, NJ. Ch. 8 pp 127-150, 2000.

18. Alexander, HR Jr., Bartlett, DL, Libutti, SK Current status of isolated hepatic perfusion

with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist. 2000;5(5):416-24.

19. Bartlett, D.L., Alexander, H.R. Isolated Hepatic Perfusion, In: American Cancer Society

Atlas Series - Hepatobiliary Cancer, Eds, L.H. Blumgart, Y. Fong, B.C. Decker, Inc., 2000, pp 213-224.

21. Bartlett, D.L. Treatment of patients with hepatic metastases. Cancer J of Sci Am. 6: S169-S176, 2000.

22. Bartlett, D.L. Peritoneal Carcinomatosis. In: Principles and Practice of Oncology, Eds. Devita, Hellman, Rosenberg. Lippincott, Williams & Wilkins, Philadelphia, PA. Pub. Ch 49 pp 2561 – 2573. 2001.


23. Bartlett DL and Fong Y. Small solitary hepatic metastases: When and how? In: Surgical Management of hepatobiliary and pancreatic disorders. Ed. Graeme J. Poston and Leslie H. Blumgart. Martin Dunitz Ltd. London, England. 2003 Ch. 6 pp 79-92.

24. AJ McCart and Bartlett, DL Vaccinia Viral Vectors In: Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 2nd Edition. Ed. Nancy Smyth Templeton. Marcel

Dekker, Inc., Pub. 2004 pp165-179. 25. Guo ZS, Bartlett, DL. Vaccinia as a vector for gene delivery. Expert Opin Biol Ther. 2004 Jun;4(6) :901-17. Review. PubMed PMID: 15036196. 25. Bartlett DL, Carr BI, Marsh JW. Cancer of the Liver. In: Principles and Practice of Oncology, 7th edition. Eds. Devita, Hellman, Rosenberg. Lippencott, Williams & Wilkins, Philadelphia. 2005 Section 4 pp 986-1008.

26. Bartlett DL, Ramanathan R,. Cancer of the Billiary Tree. In: Principles and Practice of Oncology, 7th edition. Eds. Devita, Hellman, Rosenberg. Lippincott, Williams & Wilkins, Philadelphia. 2005 Section 5 pp 1009-1034.

27. Chalikonda S, Bartlett DL. Vaccinia and Poxvirus. In: Gene Therapy for Cancer. Eds. Hunt KK, Vorburger SA, Swisher SG. Humana Press. 2006. Ch. 4. 28. AJ McCart and Bartlett, DL Vaccinia Viral Vectors In: Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 3rd Edition. Ed. Nancy Smyth Templeton. Francis and Taylor., Pub. 2008 29. Bartlett DL, Di Bisceglie AM, Dawson LA Cancer of the Liver In: Principles and Practice of Oncology, 8th edition. Eds. Devita, Hellman, Rosenberg. Lippencott, Williams & Wilkins, Philadelphia.2008. Pg. 1129-1155. 30. Bartlett DL, Ramanathan RK, Deutsch M. Cancer of the Biliary Tree In: Principles and Practice of Oncology, 8th edition. Eds. Devita, Hellman, Rosenberg. Lippencott, Williams & Wilkins, Philadelphia.2008 Pg. 1156-1185. 31. Bartlett DL, Neal, MD; Thirunavukarasu, P, Editors. Surgical Oncology: Fundamentals, Evidence-based Approaches and New Technology, Jaypee Brothers Medical Publishers, Ltd. New Delhi, India. January 2011. 32. Idrees, K, BartlettDL, Fisher, B. Surgical Oncology – Definition, History, Scope, Philosophy

in Surgical Oncology: Fundamentals, Evidence-based Approaches and New Technology, Jaypee Brothers Medical Publishers, Ltd. New Delhi, India. January 2011. Pg. 3-15.

33. Choudry, MH, Bartlett, DL. Multidisciplinary Approach in Surgical Oncology:

Fundamentals, Evidence-based Approaches and New Technology, Jaypee Brothers Medical Publishers, Ltd. New Delhi, India. January 2011. Pg. 16-22.


34. Choudry H, Bartlett DL. Malignant Peritoneal Mesothelioma (MPM) in: Regional Therapeutics for Advanced Malignancies, Ed. Goodman MD. Jaypee Brothers Medical Publishers, Ltd. New Delhi, India. May 2012. Pg. 43-57. 35. Choudry HA, Bartlett DL. “Case report: Management of malignant peritoneal

mesothelioma.” Published in Cancer Insights, UPMC, 2012 36. Khreiss M, Maduekwe U, Bartlett, DL Robotic Liver Resection in Robotic Surgery for the

General Surgeon. Ed. Oleynikov, Bills, Nova Science Publishers, Inc., Hauppauge NY March 2014. Pg. 147-164.

Invited Lectureships: 1. Cryotherapy for Liver Tumors. Postgraduate Course at Society of Surgery of the Alimentary Tract (SSAT) (San Francisco, CA. May 1996)

2. Techniques and Results of Isolated Hepatic Perfusion Chinese National Hepatobiliary and Enteric Surgery Research Center Hunan, P.R. China, April, 1997

3. Regional therapy for unresectable liver cancer (Infusion, perfusion, and other techniques). Postgraduate course at American College of Surgeons “Frontiers in Clinical Oncology” (Baltimore, MD, April 1998).

4. Management of Peritoneal Carcinomatosis Surgical Grand Rounds Montefiore Medical Center (New York, NY Jan. 21, 1998)

5. Updates in Gene Therapy for Cancer Surgical Grand Rounds Hospital of the University of Pennsylvania (Philadelphia, PA, April 4, 1998).

6. Basic Science of Oncology, Genetics of Colorectal Cancer, Adrenal Cancer, Laparoscopy in

Surgical Oncology. Salzburg-Cornell Surgical Oncology Seminar Salzburg, Austria, Feb. 15-21, 1998)

7. Regional Application of Tumor Necrosis Factor via Isolated Perfusion: Mechanisms of

Action and Current Clinical Results. Clinical Center Ground Rounds, NIH, Bethesda, Maryland September 2, 1998


8. Management of Hepatic Metastasis National Oncology forum, Chicago, Ill. October, 1999

9. Replicating Pox Viruses for Tumor Directed Gene Delivery. National Cancer Institute, Seminars in Clinical and Molecular Oncology. Bethesda, MD. January 18, 2000

10. Immunotherapy of Cancer Baxter Health Care Chicago, IL April, 2000

11. Treatment of Liver Metastases. Isolated Hepatic Perfusion Oncology Conference Ellis Fischer Cancer Center Lake of the Ozarks, Missouri May, 2000 12. “Parathyroid Imaging”

American Association of Endocrine Surgeons & British Association of Endocrine Surgeons in London, England 05/19/00-05/26/00

13. “Enhanced vaccinia - mediated anti-tumor response after specific inhibition of the cellular

immune response” American Society of Gene Therapy, Denver, CO 05/31/00-06/02/00 14. “Development of tailor-made cancer therapy” US-Japan Workshop; Maui, HW 02/17/01-02/19/01 15. “Intraperitoneal chemotherapy”. Gastric Cancer Congress (co-chair), New York, NY 04/29/01-05/02/01 16. “Systematic delivery of a replicating vaccinia expressing purine nucleoside phosphorylase

(PNP) treats subcutaneious tumors.” American Association for Cancer Research in New Orleans, LA 03/26/01-03/28/2001 17. “Intraperitoneal chemotherapy”. Gastric Cancer Congress (co-Chair) in New York, NY 04/29/01-05/02/01


18. “Use of a Tumor-Selective Vaccinia Virus Mutant to Compare Cytosine Deaminase Suicide Gene Systems”

American Society of Gene Therapy, Seattle, Washington 05/31/01-06/02/01 19. “Vaccinia virus gene therapy”. Rotterdam Cancer Institute, Rotterdam, the Netherlands 09/03/01-09/07/01 20. “Management of Hepatic Metastases.” Georgetown University Hospital Grand Rounds, Washington, D.C. November 2001 21. “Regional Perfusion for Cancer.” Central Surgical Association Annual Meeting, Pittsburgh, PA 03/07/02 22. “Hyperthermic Perfusion for Regionally Confined Metastatic Cancer.” UPMC Center for Continuing Education: St. Francis Health System, Pittsburgh, PA 04/09/02 23. “Adjuvant Therapy for Locally Advanced Pancreatic Cancer”. UPMC Center for Continuing Education: Dubois Cancer Conference; Dubois, PA 04/13/02 24. “Adjuvant Therapy for Locally Advanced Pancreatic Cancer”.

UPMC Center for Continuing Education: Brownsville General Hospital; Brownsville, PA 04/18/02

25. “Hyperthermic Perfusion for Regionally Confined Metastatic Cancer.” The College of Physicians and Surgeons of Ontario; Toronto, Canada 04/26/02 26. Tumor Board Lee Hospital, Johnstown, PA October 3, 2002 27. Tumor Board Westmoreland County Hospital 10/15/02 28. Grand Rounds West Penn Allegheny Health System, Pittsburgh, PA 10/30/02 29. Tumor Board


Lee Hospital, Johnstown, PA 10/05/02 30. Presentation to UPMC Cancer Centers Management Assembly Hillman Cancer Center, Pittsburgh, PA 12/12/02 31. A Reason to Hope Lecture Hillman Cancer Center, Pittsburgh, PA 01/23/03 32. “Surgical Management of Advanced GI Cancers" Murtha Cancer Center, Johnstown, PA 04/08/03 33. “Hyperthermic Chemoperfusion for Regionally Confined Metastatic Cancer.” Portsmouth US Naval Base, Portsmouth, VA 01/27/04 34. "Hyperthermic Chemoperfusion for Regionally Confined Metastatic Cancer" Maine Medical

Center, Portland, Maine. The Isaac M. Weber Lecture 05/13/04 35. Management of Hepatic Metastases” Maine Medical Center, Portland, Maine 05/13/04 36. “Hyperthermic Chemoperfusion for Regionally Confined Metastatic Cancer” St. Luke’s Hospital, Allentown, PA 05/20/04 37. Regional Perfusion Cancer Therapy 1/26/05 UPMC Gastroenterology, Hepatology, and Nutrition Grand Rounds 38. Gene Therapy 3/8/05 Banf 39. New Options for the Management of Liver Metastasis 3/16/05 Clinical Oncology Grand Rounds 40. What to do When the Gallbladder was perforated 4/16/05 AHPBA Gallbladder Cancer Discovered after Laparoscopic Cholecystectomy 41. Chemoperfusion for Peritoneal Malignancies 5/6/05 Heritage Valley Grand Rounds


42. Cases in Adjuvant Colorectal Cancer 5/7/05 NMCR/NOCR 43. Options for creating mutant poxviruses for oncolytic therapy 6/2/05 ASGT 44. Cape Cod Pancreatic Hepatobiliary Conference 6/18/05 45. “Liver Surgery” Congress on Multidisciplinary Treatment of Liver Cancer, Catania, Italy October 13, 2005 46. What’s New in the Surgical Management of Colorectal Metastasis, The Robert Ravdin Lecture, University of Pennsylvania, April 6, 2006. 47. Current Concepts in General Surgery and Trauma Update, Albuquerque, NM Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancies 09/07/06 48.Current Concepts in General Surgery and Trauma Update, Albuquerque, NM What’s New in the Surgical Management of Metastatic Colorectal Cancer? 09/07/06 49. University of New Mexico, Cancer Research and Treatment Center ----b(4)-------------------------------------- 09/08/06 50. Pinnacle Health Grand Rounds, Harrisburg, PA Advances in Gastrointestinal Cancer Treatment 2/22/07 51. 2nd Annual Conference International Symposium on Minimally Invasive Surgical Oncology (MISO), City of Hope, CA 3/24/07 Laparoscopic Hepatobiliary Surgery 52. Surgically Delivered Chemotherapy and Biologic Therapy for Metastatic Cancer. Roswell Park, NY 4/23/07 53. Grand Rounds, Conemaugh Memorial Medical Center, Johnstown, PA Regional Chemotherapy for Advanced Metastatic Colon Cancer 05/02/07


54. Surgically Delivered Chemotherapy and Biologic Therapy for Metastatic Cancer. Penn State College of Medicine, Hershey, PA 05/14/07 55. University of Pittsburgh Department of Surgery Grand Rounds Surgery for Advanced Metastatic Colon Cancer” 12/03/08 56. 6th Biannual Peritoneal Surface Oncology Group, Lyon, France Parietal disease: Parietal Peritonectomy, Scar removing" 11/17/08 57. Temple Grand Rounds, Philadelphia, PA “Surgery for Advanced Metastatic Colon Cancer” 01/21/09 58. Memorial Sloan-Kettering Cancer Center Distinguished Visiting Professor Lecture “Updates in Regional Perfusion Therapy” 2/16/09 59. University of Maryland Medical Center Thurston R. Adams Lecturer

"Oncolytic Pox Virus: From Bench to Bedside" 6/19/09 60. SRM University, Tamil Nadu, India "Surgery for Advanced and Metastatic Cancer" 8/17/09

61. Madras Medical College, Government General Hospital and Research Institute,

Chennai, India "Surgery for Advanced and Metastatic Cancer - Focus on Colon Cancer"

8/18/09

62. The Tamil Nadu Dr. M.G.R Medical University, Chennai, India "Oncolytic Viral Gene Therapy - A Novel Approach to the Treatment of Cancer" 8/18/09

63. Association of Surgeons of India, Chennai City Branch, Chennai, India "Surgically Delivered Chemotherapy and Regional Perfusion Techniques" 8/18/09 64. Gem Hospital, Coimbatore, Tamil Nadu, India "Robotic Surgery - The Present Status" 8/22/09


65. 4th Symposium on Peritoneal Carcinomatosis, Regensburg, Germany "CRS and HIPEC - UPMC Data" 9/17/09 66. Grand Rounds - Univ. of Oklahoma, Zion, IL campus “Updates in Regional Perfusion Therapy” 10/09/09 67. Montefiore Einstein Cancer Center Grand Rounds "Surgery for Advanced Metastatic Colon Cancer." 4/7/10 68. 2010 AAES Welcoming Address Omni William Penn, Pittsburgh, PA 4/18/10 69. 2010 American Society of Clinical Oncology, Chicago IL “Treatment of Colorectal Cancer with Peritoneal Carcinomatosis - Knife, Drugs, or Both?” June 6, 2010 70. 5th Symposium on Peritoneal Carcinomatosis, Upsala, Sweden “Diagnostic tools and staging of Peritoneal Carcinomatosis” 9/7/2010 71. Association for Academic Surgery, Washinton, DC Keynote speaker for the Career Development Course 10/1/2010 72. American College of Surgeons, Washington DC “Should cytoreductive surgery and hyperthermic intraperitoneal chemotherapy be offered to patients with carcinomatosis from colorectal cancer?” 10/06/201073. 73. Ottawa Hospital Research Institute, Ottawa, Canada “Oncolytic Vaccinia Virus: Evading Preformed Immunity” 12/17/2010 74. Great Debates In GI Malignancies, New York, NY “Peritoneal Carcinomatosis” March 25, 2011 75. Grand Rounds, George Washington University “Surgical Treatment of Colorectal Cancer” March 30, 2011 76. ASGCT, Seattle, WA Clinical Trial Results: Intralesional Injection of a Tumor Selective Oncolytic Vaccinia


Virus” May 21, 2011. 77. Advances in Colorectal Oncology, Memorial Sloan-Kettering, NY, NY “Direct Delivery of Chemotherapy and Therapeutic Biological Agents to Tumor Blood Vessels” 11/17/11. 78. Cancer of the Pancreas: Diagnosis, Medical Therapy and Legal Responsibility Pancreatic Cancer: State of the Art, Rome, Italy, 12/2-3/2011. 79. Regional Therapies for Cancer UPMC Hamot, March 7, 2012. 80. Society of Surgical Oncology Annual Meeting, Orlando, FL "Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Cancer. March 22, 2012. 81. Regional Therapy for Metastatic Colon Cancer, Grand Rounds Stamford Hospital, Connecticut – March 29, 2012 82. “Regional Therapies” Out Reach, MonGeneral Hospital, Morgantown, WV May 15, 2012 83. Outreach Lecture , Trinity Hospital System, Stubenville , OH “HIPEC.” April 12, 2012 84. Joint Cancer Symposium in Shanghai “Robotic Surgical Oncology” Shanghai, China Sept. 20, 2012 85. “An Unusual Post Operative Course - A Case Report from Pittsburgh” “8th International Peritoneal Surface Malignancy Conference, Berlin, Germany. October 31, 2012. 86. “HIPEC for Peritoneal Surface Malignancies” William A. Maddox Lectureship, University of Alabama, March 28, 2013 87. “Translational Research in Surgical Oncology” UPCI Retreat, Peterson Events Center, 6/14/13 88. “Expanding Role of Hyperthermic Intra-Cavitary Chemotherapy and Surgical Debulking of

Intraabdominal Metastatic Disease” UPMC Passavant Cancer Course, Holy Trinity Greek Orthodox Church Conference, 9/20/13 89. “Surgical Delivery of Chemotherapy” Daniel M. Miller Lectureship, Grand Rounds, University of Nebraska, 9/25/13


90. “Regional Cancer Therapies” Indiana Regional Hospital, 10/1/13 91. “How to Bring Biologic Therapies and Devices to Clinical Use” American College of Surgeons, Washington DC. 10/10/13 92. “Pancreatic Neuroendocrine Tumors“ Grand Rounds, UPMC Passavant Hospital, 1/15/14 93. “Surgical Delivery of Chemotherapy for Metastatic Colon Cancer” Grand Rounds, Mt Sinai Hospital, NY 1/28/14 RESEARCH FUNDING: ACTIVE GRANT SUPPORT:

1 R01 CA155925 (Bartlett) 08/01/2011-05/31/2016 National institute of Health “Improving Vaccinia for Peritoneal Tumors: Enhanced Distribution & Immune Evasion” Role: PI 1 P01 CA132714 (Bartlett/Kalinski) 04/01/2009-03/31/2014 National Institute of Health “Directing Tumor-specific T cells to Tumors” Project 3 (Bartlett): “Tumor Selective Oncolytic Vaccinia Virus and αDC1-Based Vaccine as a Combination Therapy for Colorectal Cancer” Role: PI project 3, Co-project leader project 1, Co-director Core A1, Director Core A3 1 R01 CA140554 (Multi-PI: Lee; Bartlett, Zeh) 06/01/2010-03/31/2015 National Institutes of Health “Multimodality Approach to Hepatic Colorectal Metastases” The main goals of this proposal are to develop a novel therapy for colorectal hepatic metastases. Role: PI 1 R01 CA140215 (Thorne) 04/01/2010 – 01/31/2015 National Institutes of Health “Enhancing Delivery and Regulating Gene Expression in Oncolytic Vaccinia Vectors” Role: Co-I 1 RO1 CA134633 (Ahrens/Kalinski) 05/01/2009-04/30/2014 National Institutes of Health (NCE) “Clinical Translation of 19F MRI To Visualize Cancer Immunotherapeutic Cells” Role: Co-I


P30 CA047904 (Davidson) 08/01/2010 – 07/31/2015 National Institutes of Health “Cancer Center Support Grant” Role: Co-I 2 T32 CA113263-06A1 (Bartlett) 07/01/2006 - 06/30/2016 National Institutes of Health *Training Grant “Postdoctoral Research Training in Biotherapy of Cancer” The objective is to provide training for surgical residents and fellows in basic science research relevant to oncology and the biological therapy of cancer. Role: Program Director Alliance for Cancer Gene Therapy (b(6)) 09/01/2012-08/31/2014 ACGT 2012 Investigator Award --b(4)---------------------------------------------------------------------- Role: Co-I Lustgarten Foundation -b(6)-------- 01/01/2013-12/31/2016 Lustgarten Foundation ------b(4)----------------------------------------------------------------------------------- Role: Co-I

Philanthropic funds for research and clinical advancement [--b(4)b(6)-----] Pseudomyxoma Peritonei (PMP) Research Fund: Initial Funding Date: 01/2009 Mesothelioma Research Fund: Initial Funding Date: 06/2009 KBM Memorial Fund for Mesothelioma Research: Initial Funding Date: 01/2011 Comprehensive Mesothelioma Program/Simmons Mesothelioma Foundation Gift: Initial Funding Date: 12/2010 Bernard Fisher Endowment Professorship Fund: Initial Funding Date: 2006 Bernard Fisher Endowed Lectureship Fund: Initial Funding Date: 2006 Koch Memorial Fund Initial Funding Date: 2004


Koch Endowment Fund (Principal Fund) Initial Funding Date: 2008 Blechman Lectureship Fund: Initial Funding Date: 09/2011

COMPLETED RESEARCH SUPPORT: 5 PO1 CA101944 (Lotze) 07/01/2005-06/30/2011 National Institute of Health “Integrating NK and DC into Cancer Therapy” Program Leaders: Michael T. Lotze and Ronald Herberman The goal is to integrating NK and DC into Cancer therapy directly into tumor or ex vivo administered as an immunogen will result in tumor destruction and elicit an effective adaptive immune response. The identification of critical biomarkers and surrogates using modern proteomic, genomic and cellomic strategies will be integrated into all projects. Role: Co-I 2 RO1 CA95128 (Kalinski) 04/01/2002-06/30/2011 National Institute of Health “Regulation of DC Activity By Memory and Effector CD8+ T cells” The major goal of this project is to evaluate the DC-modulating impact of different subpopulations of CD8+ T cells in human in vitro and mouse in vitro and in vivo models. The same models will be used to evaluate the applicability of the principle “heterologous CD8 help” from tumor-unrelated (virus-specific) CD8+ T as a supportive measure for the induction of tumor-specific Th1 and CTL responses. Role: Co-I 5 T32 CA113263 (Bartlett) 07/01/2006 - 06/30/2011 National Institute of Health “Postdoctoral Research Training in Biotherapy of Cancer” The objective is provide training for surgical residents and fellows in basic science research relevant to oncology and the biological therapy of cancer. Role: PI 5 P01 CA100327 (Storkus) 05/01/2005 – 3/31/2010 National Institute of Health “Cytokine Gene Therapy for Cancer: Preclinical Models” Evaluation of combinational cytokine gene therapies (CGT) for the treatment of peripheral cutaneous or intracranial tumors in mice. Project 2 will evaluate the impact of combinational DC-based vaccines and IL-12 CGT for treating the spontaneous metastatic B16-BL6 melanoma model. Assessment of The functional subsets and epitope spreading in therapeutic responses.


Role: Co-I 5 R01 CA100415 (Bartlett) 03/01/2004 - 02/29/2009 National Institute of Health Development of a Tumor Selective Replicating Vaccinia The goal is to explore any advances over our current vector in clinical trials in metastatic gastrointestinal cancers. The research will not only help develop vaccinia virus as a vector but should have implications for other replicating vectors used for cancer gene therapy. Role: PI 5 P01 CA100327 (Storkus) 05/01/2005 – 3/31/2010 National Institute of Health “Cytokine Gene Therapy for Cancer: Preclinical Models” Evaluation of combinational cytokine gene therapies (CGT) for the treatment of peripheral cutaneous or intracranial tumors in mice. Project 2 will evaluate the impact of combinational DC-based vaccines and IL-12 CGT for treating the spontaneous metastatic B16-BL6 melanoma model. Assessment of The functional subsets and epitope spreading in therapeutic responses. Role: Co-I 1 R21 CA115059 (Bartlett) 06/18/2006 - 05/31/2010 National Institute of Health “Isolated Hepatic Perfusion with Oxaliplatin” Regional therapies for cancer have been successful in attaining partial and complete responses in patients with melanoma and metastatic colorectal cancer. Advancing these therapies requires attention to the mode of cell death and enabling sequestration of proangiogenic and stromagenic factors such as the nuclear protein HMGB1; evaluation of the role of plasmacytoid dendritic cells in mediating immunosuppression following recruitment and HMGB1 stimulation is a secondary goal of this proposal. Role: PI Pittsburgh Foundation (Bartlett) 07/01/2002 - 06/30/2005 Pittsburgh Foundation Isolated Hepatic Perfusion with Oxaliplatin for Colorectal Liver Metastases The major goal of this project is to provide for better regional treatments for liver tumors that may lead to cures or survival prolongation in patients who otherwise have no viable therapeutic options using Oxaliplatin. Celgene (Bartlett) 04/1/2002 - 03/31/2006 Celgene A Phase II Trial of Oral Thalidomide as -----b(4)-----------------------------------------------------------------------------------------------------------

Documents

CTGTAC CV: David Bartlett, M.D. - Food and Drug … Address: University of Pittsburgh E-Mail: [email protected] Dept. of Surgery 5150 Centre Avenue Business Phone: 412-692-2852 UPMC